Kestra Medical price target raised to $27 from $25 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Kestra Medical (KMTS) to $27 from $25 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.